No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
SLS Sellas Life Sciences
- 1.410
- +0.010+0.71%
Close May 31 16:00 ET
- 1.440
- +0.030+2.12%
Post 19:20 ET
81.43MMarket Cap-1305P/E (TTM)
1.490High1.390Low571.47KVolume1.390Open1.400Pre Close819.91KTurnover1.05%Turnover RatioLossP/E (Static)57.75MShares1.91452wk High8.39P/B76.58MFloat Cap0.49952wk Low--Dividend TTM54.31MShs Float554.500Historical High--Div YieldTTM7.14%Amplitude0.499Historical Low1.434Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Can SELLAS Life Sciences Group (NASDAQ:SLS) Afford To Invest In Growth?
Solaris Resources Announces $35 Million Bought Deal Offering
Strong Buy Rating on SELLAS Life Sciences Amid Progress in AML Treatment Pipeline
Express News | SELLAS Life Sciences Gr Q1 2024 Adj EPS $(0.21) Misses $(0.16) Estimate
SELLAS Life Sciences 1Q Loss/Shr 21c >SLS
SELLAS Life Sciences 1Q Loss/Shr 21c >SLS
Sellas Life Sciences | 10-Q: Quarterly report
Comments
$Sellas Life Sciences(SLS.US$ Solaris Resources announces $35 million bought deal offering
• Solaris Resources (SLS:CA) entered into an agreement pursuant to which the underwriters have agreed to purchase, on a bought deal basis, 7,150,000 common shares of the Company at $4.90 for gross proceeds of approximately $35,035,000 million.
• The Company has also granted the Underwriters an option to purchase up to an additional 1,072,500 common shares, representing 15% of the size of the offering.
...
• Solaris Resources (SLS:CA) entered into an agreement pursuant to which the underwriters have agreed to purchase, on a bought deal basis, 7,150,000 common shares of the Company at $4.90 for gross proceeds of approximately $35,035,000 million.
• The Company has also granted the Underwriters an option to purchase up to an additional 1,072,500 common shares, representing 15% of the size of the offering.
...
2
$Sellas Life Sciences(SLS.US$ I bought more. 🖕🩳🔥
7
$Sellas Life Sciences(SLS.US$
NEWS
SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level
SELLAS Life Sciences Group, Inc. announces positive Phase 2 preliminary data of SLS009 in relapsed/refractory acute myeloid leukemia (r/r AML), achieving a 100% response rate in patients with ASXL1 mutation at the optimal dose level. The company has filed IP protection related to the ASXL1 mutation, sh...
NEWS
SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level
SELLAS Life Sciences Group, Inc. announces positive Phase 2 preliminary data of SLS009 in relapsed/refractory acute myeloid leukemia (r/r AML), achieving a 100% response rate in patients with ASXL1 mutation at the optimal dose level. The company has filed IP protection related to the ASXL1 mutation, sh...
2
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg